Chief Marketing Officer · Nautilus Biotechnology, Inc. · Nautilus Biotechnology, Inc. — Stock Option (Right to Buy)
Side
A
Value
—
Shares
160.0K
Price
—
Executed
Mar 2, 2026
Disclosed
Mar 4, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Mar 2 executedMar 4, 2026 disclosed
NAUT · daily
Yahoo Finance chart API
◉This trade, on the day it was made▼Disclosure●Material company filing◯Other disclosed buy◯Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Grant or award — administrative, little informational value
Relative size+1 / 25
No reported dollar value · new position
Filing timing0 / 15
Disclosed 2 business days after execution (deadline: 2)
Historical behavior+4 / 15
1 prior trade recorded in this security
Frequency & clustering0 / 15
No clustered activity in the dataset
Market events0 / 10
No material company filing within 60 days after the trade
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Nautilus Biotechnology, Inc. — Stock Option (Right to Buy)
Ticker
NAUT
Shares
160.0K
Price per share
$0
Execution date (reported)
Mar 2, 2026
Owned after transaction
160.0K shares
Days from execution to publication
2
What this establishes
Suzuki Kentaro filed this Form 4 reporting a grant or award of NAUT on Mar 2, 2026. It became public on Mar 4, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
Chief Marketing Officer
Suzuki Kentarocik:0002037191
Issuer
Nautilus Biotechnology, Inc.cik:0001808805
Revision history · 0
No field has changed since this record was first ingested.
